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Vascular dementiaEpidemiological studies show that vascular risk factors (e.g. atherosclerosis, diabetes, homocysteine, hyper-
tension or cholesterol) may play a role in the development of Alzheimer's disease. Animal models may help
to discover the role of vascular risk factors on cognition. In the present project we treated male Sprague Dawley
rats with a diet containing homocysteine (hyperhomocysteinemia) or cholesterol (hypercholesterolemia) for
5 months or exposed the rats to ethanol (20% in drinking water) or a combination of cholesterol+ethanol
(mix) for 12 months. Our experiments show that all 3 treatments (homocysteine, cholesterol, ethanol) declined
spatial memory in the 8-arm radial maze, reduced the number of cholinergic neurons and induced blood–brain
barrier leakage in the cortex. Rats treated with cholesterol also displayed markedly enhanced inﬂammation in
the cortex. Levels of amyloid precursor protein, beta-amyloid(1–42), aswell as tau and phospho-tau 181were sig-
niﬁcantly enhanced in the cortex of cholesterol-fed rats. A combination of ethanol and cholesterol did not further
potentiate the effects on spatial memory, cholinergic neurons and blood–brain barrier leakage. The data suggest
that chronic mild vascular risk factors over months induce small lesions of the brain capillaries in the cortex,
which may contribute to the development of vascular dementia or also Alzheimer's disease.
© 2012 Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
1.1. Alzheimer's disease (AD)
AD is characterized by cerebrovascular damage and neuronal dys-
function leading to progressive cognitive decline. The hallmark pa-
thologies include beta-amyloid (Aβ) deposition in brain (plaques)
and vessels (Aβ-angiopathy), neuroﬁbrillary tangles containing
hyperphosphorylated tau, blood–brain barrier leakage and increased
microglial reactivity as well as inﬂammatory processes. Blood–brain
barrier dysfunction is associated with a reduction of cerebral blood
ﬂow, hypoxia and accumulation of neurotoxic molecules in brain pa-
renchyma [1,2]. The amyloid hypothesis suggests that the accumula-
tion of Aβ is the most important cascade for the development of AD
[3]. Aβ-peptides (40, 42 or 43 amino acids) originate from the
membrane-associated amyloid precursor protein (APP) by cleavage
with α-, β- and γ-secretases and a dysbalance in Aβ-production and
clearance may trigger neurodegeneration [3]. Vascular risk factors
(e.g. cholesterol, homocysteine or ethanol) over long periods may. Alzheimer's Res., Innsbruck
ria. Tel.: +43 512 504 23712;
mpel).
).
C BY-NC-ND license.cause such a dysfunctional Aβ-clearance as well as blood–brain barri-
er impairment and possibly initiate cerebrovascular dysfunction or
inﬂammatory processes leading to the development of AD [4–8].
1.2. Vascular dementia (vaD)
AD and vaD share many risk factors suggesting a related pathogen-
esis [9]. The differentiation of AD from vaD is very difﬁcult, because
many symptoms of both diseases are overlapping. Thus, the differentia-
tion is based on evidence of cerebrovascular dysfunction in vaD [8]. In-
deed, cerebral vessel pathology results in blood–brain barrier leakage
and such multiple cortical infarcts (silent strokes) may play a major
role in development of vaD. This is accompanied by ischemic changes
with cerebral hypoperfusion and oxidative stress. Clinical symptoms
are multifaceted depending on location and size of the stroke lesions
which are often asymptomatic for a long period. Vascular risk factors,
such as cholesterol, homocysteine and ethanol may play an important
role in the development of vaD [10] which is suggested by the fact
that vaD is potentially preventable by life style modiﬁcation and
counteracting vascular risk factors [11].
1.2.1. The cerebrovascular system
In contrast to leaky vessels in peripheral organs [12], the blood–
brain barrier restricts entry of polar molecules into the brain. Nutrients
such as vitamins, glucose, and amino acids cross the blood–brain barrier
Fig. 1. (A) Spatial learning and long-termmemory performancewas assessed in the partial-
ly baited eight-arm radialmaze. For spatial navigation small high contrast visual cues (trian-
gle, vertical bars, cross and squares) were placed above the doors of four arms and on the
corresponding walls. Four arms were baited with food pellets and the trial ended when all
baits were found or after 10 min exceeded. (B) Rat brains were sectioned into 60 μm slices
which were stained for the enzyme choline-acetyltransferase (ChAT). The number of
ChAT-positive neurons located in the nucleus basalis of Meynert (small insert) was counted
under the microscope. (C) Inﬂammatory markers were measured by multiplex ELISA. For
the ELISA cortex extracts were added to pre-spotted plates, immune-detection was
performed and the luminescent signal was evaluated by the Searchlight imaging and anal-
ysis system. (D) Blood–brain barrier leakagewas assessed by using immunohistochemistry
against rat immunoglobulin G (IgG). Rat IgG-positive spots (small insert) in the cortexwere
counted under the microscope at a 40× magniﬁcation.
B, adapted from Pirchl et al. [21]); D, adapted from Ehrlich et al. [22].
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blood–brain barrier [14,15], but they can be transported into the brain
via speciﬁc receptors expressed in brain endothelium under physiolog-
ical or pathological conditions [16,17]. Intact neurovascular functions
are necessary for proper neuronal structure and function. Thus, pericyte
deﬁciency leads to microvascular degeneration and brain accumulation
of toxic substances (e.g. Aβ) preceding neuronal degenerative changes,
learning and memory impairment and neuroinﬂammatory response
[18,19].
1.3. Methodological aspects
1.3.1. Treatment of rats
Male Sprague Dawley rats (aged 6 months) were housed at the An-
imal Department of the Medical University Innsbruck and had free ac-
cess to food and tap water with a 12/12 h light–dark circle. All animal
experiments were approved by the Austrian Ministry of Science. The
diet of the control animals contained following ingredients: 450 g/kg
cornstarch, 140 g/kg casein, 155 g/kg maltodextrin, 100 g/kg sucrose,
40 g/kg soybean oil, 50 g/kg ﬁber, 35 g/kg mineral mix, 1.8 g/kg
L-cystine, 1.4 g/kg choline chloride, 0.008 g/kg butylhydroxytoluol,
10 g/kg vitamin mix (without folic acid), 1 g/kg chocolate aroma and
0.002 g/kg folic acid (Ssniff special diet GmbH; Soest Germany). The
animals of the cholesterol group were fed for 5 months (n=10)
or 12 months (n=12) with additional 50 g/kg cholesterol [20].
The animals of the homocysteine group were fed with additional
3 g / kg dl-homocysteine for 5 months (n=9) or 15 months (n=
10) [21]. The animals of the ethanol group were treated with 20%
ethanol in drinking water ad libitum for 12 months (n=12) [22].
The animals of the cholesterol-homocysteine mix group were treat-
ed with a combined diet of 3 g ⁄ kg dl-homocysteine and 5% choles-
terol for 5 months and the animals of the cholesterol ethanol mix
group (n=12) were fed with a diet containing 5% cholesterol and
20% ethanol in drinking water [21,22].
1.3.2. Cognition in the partially baited eight-arm radial maze
Spatial learning and long-termmemory performancewas assessed in
the partially baited eight-arm radial maze (Fig. 1A), a well-established
method to explore learning and memory in a controlled environment,
as recently described byus in detail [21]. Themaze consists of eight iden-
tical arms with side panels and sunk-in-food cups at the end radiating
from a circular platform. For spatial navigation small high contrast visual
cues (triangle, vertical bars, cross and squares) were placed above the
doors of four arms and on the corresponding walls. Four arms were
baited with food pellets (chocolate cereals) and the trial ended when
all baits were found or after 10 min exceeded. The task for the animals
was to ﬁnd all baits in respective arms without visiting unbaited arms.
The animals were restricted to food before the learning sessions were
started to increase motivation. In a shaping session the rats were habit-
uated to the testing procedures to decrease stress. In ﬁve training ses-
sions (with each ﬁve trials) the animals had to learn the task. After
three weeks of the last session the retention (ﬁve trials) was performed
to investigate long-term memory performance. Memory errors were
quantiﬁed according to Jarrard et al.'s deﬁnition [23]. The whole experi-
ments was automatically controlled andmonitored by a computer with
MAZESOFT Software (Version 8.1.9).
1.3.3. Cholinergic neurons
The cholinergic neurons located in the septumand nucleus basalis of
Meynert (nbM; Fig. 1B) play an important role in cognition and memo-
ry and are severely impaired in AD [24]. For immunohistochemistry
brains were removed and ﬁxed in 4% paraformaldehyde. Then brains
were frozen under CO2 snow and sectioned into 60-μm slices with a
cryostate (Leica Jung CM3000). Slices were immunohistochemically
stained for the enzyme choline-acetyltransferase (ChAT) that serves
as markers for cholinergic neurons. ChAT-positive neurons of thenucleus basalis of Meynert (nbM) between Bregma −0.7 to −3.1
were counted at a 40× magniﬁcation under the microscope.1.3.4. Inﬂammation
Inﬂammation plays a role in both AD as well as in vaD [25]. In our
studies levels of inﬂammatory markers (e.g. interleukine-1β, tumor-
necrosis-factor-α, monocytochemotactic-protein-1, macrophage-
inﬂammatory-protein-2) in the cortex were explored by multiplex
ELISA (Fig. 1C) (Searchlight, Aushon Biosystems), as described re-
cently by us [21]. Brieﬂy, the brains were removed, the frontal cortex
dissected and immediately frozen. Cortex tissue was homogenized in
ice-cold sodium phosphate buffer with a protease inhibitor, centrifuged
and subsequently the supernatant was added to the prespotted plates
and incubated for 3 h. After washing the biotinylated antibody was
added and incubated for 30 min. After being washed streptavidin-
horseradish peroxidise reagent was added and the luminescent signal
was detected by the Searchlight CCD imaging and analysis system. Sam-
ple values were calculated from the standard curve in a liner range.1.3.5. Vascular disruptions
Vascular risk factors may induce leakage of the blood–brain barri-
er allowing certain substances to migrate into the brain. For immuno-
histochemistry brains were removed and were frozen under CO2
snow and sectioned into 20-μm sections with a cryostate (Leica
Jung CM3000). Blood–brain barrier integrity was assessed by immu-
nohistochemical staining against rat immunoglobulin G (IgG), as de-
scribed in detail by us [21]. IgG-positive spots in the cortex were
counted under the microscope at a 40× magniﬁcation.
Table 1
Effects of vascular risk factors in Sprague Dawley rats in vivo.
Risk factor Spatial
memory
Cholinergic
neurons
Inﬂammation Blood–brain
barrier
leakage
Cholesterol ↓ ↓ ↑ ↑
Homocysteine ↓ ↓ – ↑
Ethanol ↓ ↓ – ↑
Ethanol+cholesterol ↓ ↓ – ↑
Homocysteine+cholesterol ↓ ↓ ↑
Spatial memory was tested on the eight arm radial maze. The number of cholinergic
neurons was measured by immunohistochemistry. Inﬂammatory markers were
analyzed by multiplex Searchlight ELISA. Blood–brain barrier leakage was indirectly
shown by anti-rat immunoglobulin G histochemistry. (↓ decreased, ↑ increased, – no
change).
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Treatment with the vascular risk factors cholesterol, homocyste-
ine and ethanol over months resulted in memory impairment, dys-
function of the cholinergic system, blood–brain barrier leakage and
inﬂammation in adult Sprague Dawley rats.
1.5. Effects of hypercholesterolemia
Cholesterol may play a role in development of AD possibly by
inﬂuencing APP processing which leads to enhanced levels of Aβ
[26]. Indeed, inhibitors of cholesterol synthesis (statins) may have a
protective effect against AD [27] and the C-terminal transmembrane
domain C99 of APP speciﬁcally binds cholesterol and favors the
amyloidogenic pathway in cells by promoting localization of C99 in
lipid rafts [28,29]. We have shown that treatment of rats with a 5%
cholesterol-rich diet for 5 months caused spatial memory deﬁcits, a
dysfunction of the cholinergic system, blood–brain barrier leakage
and inﬂammation [20]. In the cortex of cholesterol-fed rats levels of
APP, Aβ(1–42), as well as tau and phospho-tau 181 were signiﬁcantly
enhanced [10]. Thus, hypercholesterolemia in rats resembled some
AD-like pathology and has been suggested to provide a good model
to study AD development as well as cerebrovascular dysfunction [10].
1.6. Effects of hyperhomocysteinaemia
Elevated homocysteine plasma levels may enhance the risk for devel-
oping AD or vaD [30]. It is well established that hyperhomocysteinaemia
induces memory and learning disabilities in several animal models
[21,31]. We have shown that in adult Sprague Dawley rats hyper-
homocysteinaemia for 5 months markedly affected spatial memory per-
formance and the number of cholinergic neurons in the nbM [21]. In the
cortex blood–brain barrier leakagewas enhanced after 12 months homo-
cysteine treatment, but inﬂammationwas not induced [21]. Interestingly,
hyperhomocysteinaemia in rats did not show an AD-like pathology, such
as Aβ-plaques, tau-pathology or inﬂammation, but resulted in spatial
memory impairment and dysfunction of the cholinergic system which
might be initiated by blood–brain barrier impairment [21].
1.7. Effects of ethanol
Ethanol consumption might cause cerebrovascular diseases, such as
stroke and vaD, and may induce cognitive decline and cholinergic dys-
function [10] and AD [32–34]. However, there is increasing evidence
that moderate chronic ethanol has protective effects on AD develop-
ment [35]. We have shown that long-term treatment (12 months) of
adult Sprague Dawley rats with 20% ethanol in drinking water ad
libitum resulted in cognitive decline, cholinergic dysfunction and
blood–brain barrier leakage, but did not dramatically induce cortical in-
ﬂammation [22]. In the cortex of ethanol treated rats only monocyte
chemotactic-protein-1 (MCP-1) was enhanced suggesting that MCP-1
may take part in a signaling cascade deviating from its role as a
pro-inﬂammatory cytokine [22]. MCP-1 is also secreted by activated mi-
croglia cells [36] and indeed, aftermoderate long-termethanol treatment
cortical microglia reactivity was enhanced in rats [22]. Interestingly, eth-
anol did not resemble an AD-like pathology, but rather suggested a
protective effect against AD development [22]. In summary, the cerebro-
vascular risk factor ethanol may markedly contribute to some pathology
of vaD, but did not resemble an AD-like neuropathology [22].
1.8. Combination of vascular risk factors
The combination of ethanol and cholesterol did not dramatically
affect the changes in spatial memory, cholinergic neurons, blood–
brain barrier impairment and inﬂammation [22]. However, ethanol
counteracted some of the cholesterol-induced effects: it reducedweight, plasma cholesterol levels and cortical Aβ(1–40) and Aβ(1–42)
content, suggesting a protective role of ethanol in the development
of AD [22]. In contrast, cholesterol did not markedly affect the ethanol-
induced changes showing only a prominent reduction of plasma ethanol
levels [22]. Cholesterol may modulate the absorption of ethanol into the
blood, possibly due to a prolonged retention of ethanol in the stomach
after cholesterol-rich nutrition [37]. Taken together, a combined treat-
ment of ethanol and cholesterol did not potentiate the effects of a single
treatment but rather counteracted some of the ethanol- or cholesterol-
induced effects [22]. A combined cholesterol and homocysteine diet for
5 months resulted in spatial impairment and reduced cholinergic neu-
rons similar to a single treatment, but homocysteine counteracted the
cholesterol-induced inﬂammation and reduced slightly cortical blood–
brain barrier leakage.
1.9. Long-term versus short-term effects: differences
Short-term (5 months) 5% cholesterol diet markedly reduced spa-
tial memory performance, the number of cholinergic neurons in the
nbM, induced inﬂammation as well as blood–brain barrier leakage
in the cortex [20]. Interestingly, chronic ethanol or cholesterol treat-
ment for 12 months had similar effects in vivo, although they were
not as pronounced as the 5-month cholesterol effects. Long-term
treatment of cholesterol did not result in inﬂammation and the
changes were not as pronounced, most likely due to adaptive and
compensatory mechanisms. This is in line with Pirchl et al. [21],
who reported that short-term (5 months) treatment with the vascu-
lar risk factor homocysteine had more severe effects than long-term
(15 months) homocysteine treatment. The cholinergic impairment
after prolonged exposure to homocysteine was possibly counteracted
by the upregulation of nerve growth factor [21], which is the most po-
tent trophic molecule to support survival of cholinergic neurons [38].
2. Conclusion
Moderate chronic vascular risk factors, such as cholesterol, homo-
cysteine or ethanol impair spatial memory, decline cholinergic neurons
and induce blood–brain barrier leakage in rats in vivo which may con-
tribute to the development of vascular dementia or Alzheimer's disease
(Table 1).
Conﬂict of interest
None.
Acknowledgments
This study was supported by the Austrian Science Funds (P191220-
B05 and L429-B05). We thank Ursula Kirzenberger–Winkler for her ex-
cellent technical help.
95D. Ehrlich, C. Humpel / Journal of the Neurological Sciences 322 (2012) 92–95References
[1] Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's dis-
ease and other disorders. Nat Rev Neurosci 2011;12:723–38.
[2] Kalaria RN. Vascular basis for brain degeneration: faltering controls and risk fac-
tors for dementia. Nutr Rev 2010;68(Suppl. 2):74–87.
[3] Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and
problems on the road to therapeutics. Science 2002;297:353–6.
[4] Shepardson NE, Shankar GM, Selkoe DJ. Cholesterol level and statin use in
Alzheimer disease: II. Review of human trials and recommendations. Arch Neurol
2011;68:1385–92.
[5] Brust JC. Ethanol and cognition: indirect effects, neurotoxicity and neuroprotection:
a review. Int J Environ Res Public Health 2010;7:1540–57.
[6] Zhuo JM, Wang H, Praticò D. Is hyperhomocysteinemia an Alzheimer's disease
(AD) risk factor, an AD marker, or neither? Trends Pharmacol Sci 2011;32:
562–71.
[7] Dickstein DL, Walsh J, Brautigam H, Stockton Jr SD, Gandy S, Hof PR. Role of vas-
cular risk factors and vascular dysfunction in Alzheimer's disease. Mt Sinai J
Med 2010;77:82–102.
[8] Humpel C. Chronic mild cerebrovascular dysfunction as a cause for Alzheimer's
disease? Exp Gerontol 2011;46:225–32.
[9] De la Torre JC. Alzheimer's disease as a vascular disorder. Stroke 2002;33:1152–62.
[10] Mostofsky E, Burger MR, Schlaug G, Mukamal KJ, RosamondWD, MittlemanMA. Al-
cohol and acute ischemic stroke onset: the stroke onset study. Stroke 2010;41:
1845–9.
[11] Lee AY. Vascular dementia. Chonnam Med J 2011;47:66–71.
[12] Mann GE, Zlokovic BV, Yudilevich DL. Evidence for a lactate transport system in
the sarcolemmal membrane of the perfused rabbit heart: kinetics of unidirection-
al inﬂux, carrier speciﬁcity and effects of glucagon. Biochim Biophys Acta
1985;819:241–8.
[13] Zlokovic BV, Apuzzo ML. Cellular and molecular neurosurgery: pathways from
concept to reality—part I: target disorders and concept approaches to gene ther-
apy of the central nervous system. Neurosurgery 1997;40:789–803.
[14] Zlokovic BV, Segal MB, Begley DJ, Davson H, Rakić L. Permeability of the blood–ce-
rebrospinal ﬂuid and blood–brain barriers to thyrotropin-releasing hormone.
Brain Res 1985;358:191–9.
[15] Zlokovic BV, Begley DJ, Chain-Eliash DG. Blood–brain barrier permeability to
leucine-enkephalin, D-alanine2-D-leucine5-enkephalin and their N-terminal
amino acid (tyrosine). Brain Res 1985;336:125–32.
[16] Zlokovic BV, Mackic JB, Djuricic B, Davson H. Kinetic analysis of leucine-enkephalin
cellular uptake at the luminal side of the blood–brain barrier of an in situ perfused
guinea-pig brain. J Neurochem 1989;53:1333–40.
[17] Zlokovic BV, Hyman S, McComb JG, Lipovac MN, Tang G, Davson H. Kinetics of
arginine-vasopressin uptake at the blood–brain barrier. Biochim Biophys Acta
1990;1025:191–8.
[18] Bell RD, Winkler EA, Singh I, Sagare AP, Deane R, Wu Z, et al. Apolipoprotein E
controls cerebrovascular integrity via cyclophilin A. Nature 2012;485:512–6.
[19] Bell RD, Winkler EA, Sagare AP, Singh I, LaRue B, Deane R, et al. Pericytes control
key neurovascular functions and neuronal phenotype in the adult brain and dur-
ing brain aging. Neuron 2010;68:409–27.
[20] Ullrich C, Pirchl M, Humpel C. Hypercholesterolemia in rats impairs the choliner-
gic system and leads to memory deﬁcits. Mol Cell Neurosci 2010;45:408–17.
[21] Pirchl M, Ullrich C, Humpel C. Differential effects of short- and long-term hyper-
homocysteinemia on cholinergic neurons, spatial memory and microbleedings in
vivo in rats. Eur J Neurosci 2010;32:1516–27.[22] Daniela Ehrlich, Michael Pirchl, Humpel Christian. Effects of long-term moderate
ethanol and cholesterol on cognition, cholinergic neurons, inﬂammation and vas-
cular impairment in rats. Neuroscience 2012;205:154–66.
[23] Jarrard LE, Okaichi H, Steward O, Goldschmidt RB. On the role of hippocampal
connections in the performance of place and cue tasks: comparisons with damage
to hippocampus. Behav Neurosci 1984;98:946–54.
[24] Mufson EJ, Counts SE, Perez SE, Ginsberg SD. Cholinergic system during the pro-
gression of Alzheimer's disease: therapeutic implications. Expert Rev Neuroether
2008;8:1703–18.
[25] Helmy AA, Abdel Naseer MM, El Shaﬁe S, Nada MA. Role of interleukin 6 and
alpha-globulins in differentiating Alzheimer and vascular dementias. Neurodegener
Dis 2012;9(2):81–6 [Epub ahead of print].
[26] Ehehalt R, Keller P, Haass C, Thiele C, Simons K. Amyloidogenic processing of the
Alzheimer beta-amyloid precursor protein depends on lipid rafts. J Cell Biol
2003;160:113–23.
[27] Tong XK, Nicolakakis N, Fernandes P, Ongali B, Brouillette J, Quirion R, et al. Sim-
vastatin improves cerebrovascular function and counters soluble amyloid-beta,
inﬂammation and oxidativestress in aged APP mice. Neurobiol Dis 2009;35:
406–14.
[28] Beel AJ, Sakakura M, Barrett PJ, Sanders CR. Direct binding of cholesterol to the
amyloid precursor protein: an important interaction in lipid–Alzheimer's disease
relationships? Biochim Biophys Acta 2010;1801:975–82.
[29] Barrett PJ, Song Y, Van Horn WD, Hustedt EJ, Schafer JM, Hadziselimovic A, et al.
The amyloid precursor protein has a ﬂexible transmembrane domain and binds
cholesterol. Science 2012;336:1168–71.
[30] Ravaglia G, Forti P, Maioli F, Martelli M, Servadei L, Brunetti N, et al. Homocysteine
and folate as risk factors for dementia and Alzheimer disease. Am J Clin Nutr
2005;82:636–43.
[31] Stefanello FM, Monteiro SC, Matte' C, Scherer EB, Netto CA, Wyse AT. Hyper-
methioninemia increases cerebral acetylcholinesterase activity and impairs memory
in rats. Neurochem Res 2007;32:1868–74.
[32] Floyd EA, Young-Seigler AC, Ford BD, Reasor JD, Moore EL, Townsel JG, et al.
Chronic ethanol ingestion produces cholinergic hypofunction in rat brain. Alcohol
1997;14:93–8.
[33] Arendt T. Impairment in memory function and neurodegenerative changes in the
cholinergic basal forebrain system induced by chronic intake of ethanol. J Neural
Transm Suppl 1994;44:173–87.
[34] Arendt T, Brückner MK, Krell T, Pagliusi S, Kruska L, Heumann R. Degeneration of
rat cholinergic basal forebrain neurons and reactive changes in nerve growth fac-
tor expression after chronic neurotoxic injury—II. Reactive expression of the
nerve growth factor gene in astrocytes. Neuroscience 1995;65:647–59.
[35] Anstey KJ, Mack HA, Cherubin N. Alcohol consumption as a risk factor for demen-
tia and cognitive decline: meta-analysis of prospective studies. Am J Geriatr Psy-
chiatry 2009;17:542–55.
[36] Kaul M, Garden GA, Lipoton SA. Pathways to neuronal injury and apoptosis in
HIV-associated dementia. Nature 2001;410:988–94.
[37] Gentry TR. Effect of food on the pharmacokinetics of alcohol absorption. Alcohol
Clin Exp Res 2000;24:403–4.
[38] Levi-Montalcini R, Skaper SD, Dal Toso R, Petrelli L, Leon A. Nerve growth factor:
from neurotrophin to neurokine. Trends Neurosci 1996;19:514–20.
